Nogapendekin Alfa Inbakicept: A New Drug for Non-Muscle-Invasive Bladder Cancer

What Is Nogapendekin Alfa inbakicept?

Nogapendekin Alfa Inbakicept, also known as N-803 immunotherapy, is a medicine approved by the Food and Drug Administration (FDA) to treat non-muscle invasive bladder cancer (NMIBC).

Your physician may prescribe this medicine to you if your cancer has not responded to BCG treatment. BCG, or Bacillus Calmette-Guérin, is a therapy administered to your bladder to stimulate your immune system and help combat the cancer.

However, if this treatment fails, your physician may suggest Nogapendekin Alfa Inbakicept, which is a next-generation cancer immunotherapy, as the next course of treatment.

This medicine is also applicable to patients with carcinoma in situ (CIS) regardless of the presence of papillary tumors, which are small growths that may occur with CIS.

Carcinoma in situ (CIS) refers to a type of bladder cancer that is superficial and has not advanced to the deeper layers of the bladder.

Nogapendekin Alfa Inbakicept was approved on April 22, 2024, giving people with NMIBC that does not respond to BCG a new treatment option.

It acts as a BCG-unresponsive bladder cancer immunotherapy when BCG alone is not effective and is considered both safe and effective, with minimal side effects.

How Does Nogapendekin Alfa Inbakicept Work?

Nogapendekin Alfa Inbakicept works by helping your immune system fight cancer cells.

This medicine is classified as an interleukin (ATC code: L03AC03), and it belongs to a group of medicines called interleukin-15 (IL-15) receptor agonists, which help activate the immune system.

It is a special type called an IL-15 superagonist cancer therapy, designed to boost immune cells even more strongly to fight cancer.

It boosts your immune responses by activating CD4+ and CD8+ T cells, which are your body’s fighting cells that help attack cancer, as well as natural killer (NK) cells, acting as an NK cell activating therapy to help destroy cancer cells.

Why Is Nogapendekin Alfa Inbakicept Important in Cancer Immunotherapy?

It is important in cancer immunotherapy because Nogapendekin Alfa Inbakicept helps your immune system fight bladder cancer when other treatments, like BCG, do not work.

Our bladder is a hollow, balloon-like organ that holds urine. Non-muscle invasive bladder cancer is a type of cancer that grows on the lining of the bladder but has not spread into the muscle layer underneath. This is the most common form of bladder cancer.

If your NMIBC is at a higher risk of growing (intermediate or high risk), your doctor may first recommend BCG treatment. However, for about 30-40% of people, BCG may not work long-term.

When BCG does not work or stops working, there are only a few treatment options before your doctor may suggest surgical removal of the bladder.

Nogapendekin alfa inbakicept offers a new option that may help you fight the cancer while preserving your bladder, giving you hope for a better outcome without immediate surgery.

How Effective Is Nogapendekin Alfa Inbakicept in Cancer?

The effectiveness of Nogapendekin Alfa Inbakicept was studied in a clinical trial called QUILT-3.0. The trial included 77 adults with high-risk non-muscle invasive bladder cancer that did not get better after BCG treatment, with or without small growths called papillary tumors.

In the trial, patients received Nogapendekin Alfa Inbakicept directly into the bladder along with BCG. Some patients also received ongoing maintenance treatment for up to 37 months.

Doctors checked tumor status with cystoscopy (looking inside the bladder) and urine tests every three months for up to two years. Biopsies were done as needed in the first six months.

The main goal was to determine how many patients achieved a complete response (CR), meaning no cancer could be detected. The CR rate was 62%. More than half of those who responded had their cancer stay away for at least 12 months, and 40% for at least 24 months.

How Is Nogapendekin Alfa Inbakicept Administered?

This treatment is combined with BCG in a single syringe and administered directly into your bladder through a catheter.

Your urologist or another qualified healthcare provider performs this procedure once a week for six weeks. The process is the same as when BCG is given alone. After the treatment, you will follow the same care instructions as after BCG therapy.

If your tumor does not shrink after three months, your doctor may recommend a second course of treatment. Your urologist will also manage your care after treatment, so your healthcare team stays the same throughout the process.

What Are the Safety and Side Effects of Nogapendekin Alfa Inbakicept?

For your safety, before starting treatment with Nogapendekin Alfa Inbakicept, tell your doctor if you are pregnant or think you might be pregnant.

After treatment with Nogapendekin Alfa Inbakicept, let your doctor know if irritable bladder symptoms or red-colored urine last longer than 24 hours.

If you are allergic to any ingredient in Nogapendekin Alfa Inbakicept, make sure to discuss this with your healthcare provider.

Also, inform your doctor about:

• All the medicines and supplements you take, including prescription, over-the-counter, vitamins, and herbal products.

• If you are pregnant or planning to become pregnant.

• Any symptom of a urinary tract infection, like pain or burning when you urinate, frequent or urgent need to urinate, or pain or pressure in your lower abdomen or pelvic area.

If you cannot attend your scheduled appointment(s), inform your healthcare provider as soon as possible and reschedule at a time that works for you.

Side Effects of Nogapendekin Alfa Inbakicept

The most common side effects you may experience (in 15% or more of people), including changes in lab tests, are

• Increased creatinine levels.

• Pain when you urinate.

• Urinating more often.

• Sudden urges to urinate.

• Blood in your urine.

• Urinary tract infections.

• Higher potassium levels.

• Muscle or joint pain.

• Chills.

• Fever.

Who May Benefit Most From Nogapendekin Alfa Inbakicept?

You will benefit most from Nogapenekin Alfa Inbakicept if

• You have high-risk NMIBC with carcinoma in situ.

• Your NMIBC did not respond or is no longer responding to BCG therapy alone (BCG-unresponsive)

• Your NMIBC remains confined to the inner lining of the bladder and has not spread into the underlying muscle (carcinoma in situ or CIS)

• Your NMIBC may have small, finger-like tumor growths that extend from the bladder wall into the bladder cavity (papillary disease)

Conclusion

Nogapendekin Alfa Inbakicept is a new medicine for people with a type of bladder cancer that has not improved with BCG treatment. It is directly injected into your bladder once a week for 6 weeks.

This medicine works as an IL-15 cytokine, which helps your immune system recognize and attack cancer cells. In studies, about 7 out of 10 patients saw their cancer completely disappear, and the effect lasted, on average, over 2 years. The side effects of this medicine are very mild and tolerable; hence, it is considered a safe and effective treatment for bladder cancer that does not respond to BCG.

Consult a bladder cancer specialist online if you have questions about bladder cancer and its treatment.

Key Takeaways

• Nogapendekin Alfa Inbakicept is a new treatment for bladder cancer that has not improved with BCG therapy.

• It helps your immune system fight cancer through IL-15 cytokine treatment, giving your body a better chance to attack cancer cells.

• Treatment is given directly into the bladder once a week for six weeks, with follow-up doses if needed, and studies show it works for many patients with manageable side effects.

• Nogapendekin Alfa Inbakicept offers a treatment option that can help fight cancer while giving you a chance to avoid surgery and maintain your quality of life.